Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Invested Capital (2016 - 2025)

Protalix BioTherapeutics has reported Invested Capital over the past 16 years, most recently at $48.2 million for Q4 2025.

  • Quarterly results put Invested Capital at $48.2 million for Q4 2025, up 11.62% from a year ago — trailing twelve months through Dec 2025 was $48.2 million (up 11.62% YoY), and the annual figure for FY2025 was $48.2 million, up 11.62%.
  • Invested Capital for Q4 2025 was $48.2 million at Protalix BioTherapeutics, down from $52.9 million in the prior quarter.
  • Over the last five years, Invested Capital for PLX hit a ceiling of $69.9 million in Q1 2021 and a floor of -$11.5 million in Q3 2022.
  • Median Invested Capital over the past 5 years was $44.2 million (2024), compared with a mean of $30.6 million.
  • Biggest five-year swings in Invested Capital: crashed 433.55% in 2022 and later surged 4880.75% in 2024.
  • Protalix BioTherapeutics' Invested Capital stood at -$6.0 million in 2021, then plummeted by 76.28% to -$10.6 million in 2022, then soared by 605.83% to $53.8 million in 2023, then decreased by 19.71% to $43.2 million in 2024, then increased by 11.62% to $48.2 million in 2025.
  • The last three reported values for Invested Capital were $48.2 million (Q4 2025), $52.9 million (Q3 2025), and $49.9 million (Q2 2025) per Business Quant data.